BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $112 from $70 and keeps an Outperform rating on the shares. Following the “positive” regulatory update for bitopertin, the firm increased its point-of-sale to 80% and assumes that the product will be approved under an accelerated approval pathway, using already generated data. BMO sees this update as a significant positive for the Disc story, highlighting the potential for a truly disease modifying treatment.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’
- Disc Medicine upgraded to Strong Buy from Outperform at Raymond James
- Disc Medicine Gains FDA Support for Bitopertin Trial
- Disc Medicine announces feedback from FDA End of Phase 2 meeting for bitopertin
- Disc Medicine Reports Promising Phase 1b Trial Results